Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Brentuximab is an antibody-drug conjugate (ADC), which is the combination of an antibody (a
protein that binds to cells) and a chemotherapy molecule. Brentuximab works by using the
antibody portion to enter into the Hodgkin lymphoma cells and then releasing the chemotherapy
portion, which attempts to destroy the cell.
The intravenous chemotherapy drugs Adriamycin, Vinblastine and Dacarbazine (AVD) which you
will receive in this research study are approved for use in people with Hodgkin Lymphoma. A
drug called bleomycin is usually included with AVD, but since it appears to be a less
effective drug with significant potential risks, it is being replaced in this study with the
drug brentuximab.
In this research study, the investigators are looking to see whether brentuximab in
combination with AVD is effective in treating limited-stage Hodgkin Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute H. Lee Moffitt Cancer Center and Research Institute Seagen Inc. Seattle Genetics, Inc.